WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI), (ii) pimavanserin~~a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or antagonist~~, and (iii) a pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

3. The composition of claim 2, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

4. The composition of claim 1, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol (Nucynta), Teniloxazine (Lucelan, Metatone) and Venlafaxine.

5. The composition of claim 1, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

6. The composition of claim 5, wherein the NRI is Atomoxetine.

7. The composition of claim 6, wherein the dosage of Atomoxetine is 20 – 100 mg.

~~8. The composition of claim 1, wherein the non myorelaxing hypnotic is a benzodiazepine hypnotic, preferably temazepam, brotizolam, flurazepam, nitrazepam, or triazolam.~~

~~9. The composition of claim 1, wherein the non myorelaxing hypnotic is a non-benzodiazepine hypnotic, preferably a cyclopyrrolone hypnotic, preferably selected from the group consisting of zolpidem, zopiclone, and eszopiclone;~~

~~gabapentin; trazodone; diphenhydramine; suvorexant; tasimelteon; ramelteon; agomelatine; doxepin; zaleplon; doxylamine; sodium oxybate; or tiagabine.~~

~~10. The composition of claim 1, wherein the non myorelaxing hypnotic is in an immediate release formulation.~~

~~11. The composition of claim 1, wherein the non myorelaxing hypnotic is in an extended release formulation.~~

~~12. The composition of any one of claims 1-11, wherein the non myorelaxing hypnotic is zolpidem.~~

~~13. The composition of any one of claims 1-11, wherein the non myorelaxing hypnotic is trazodone.~~

~~14. The composition of claim 12, wherein the zolpidem is in an immediate release formulation with a dose of 2 – 10 mg.~~

~~15. The composition of claim 12, wherein the zolpidem is in an extended release formulation with a dose of 5 – 12.5 mg.~~

~~16. The composition of claim 1, wherein the NRI and the non myorelaxing hypnotic are formulated in a single composition.~~

~~17~~8. The composition of any one of claims 1-7~~claim 16~~, wherein the single composition is an oral administration form.

~~18~~9. The composition of claim ~~17~~8, wherein the oral administration form is a pill, tablet, troche, or capsule.

~~19~~10. The composition of any one of claims 1-~~18~~9, for use in therapy.

~~20~~11. A kit comprising a norepinephrine reuptake inhibitor (NRI) and pimavanserin~~a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or antagonist~~.

~~21~~12. Use of an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) pimavanserin~~a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or~~

~~antagonist~~ in the preparation of a medicament for the treatment of a disease or disorder associated with pharyngeal airway collapse in a subject while the subject is in a non-fully conscious state, wherein the medicament is to be administered to a subject in need thereof.

~~22~~13. The use of claim ~~21~~12, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

~~23~~14. The use of claim ~~22~~13, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

~~24~~15. The use of claim ~~21~~12, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

~~25~~16. The use of claim ~~21~~12, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

~~26~~17. The use of claim ~~25~~16, wherein the NRI is Atomoxetine.

~~27~~18. The use of claim ~~26~~17, wherein the Atomoxetine is to be administered at a dose of 20 – 100 mg.

~~28~~19. The use of claim ~~27~~18, wherein the Atomoxetine is to be administered at a dose of 25 – 75 mg.

~~29. The use of claim 21, wherein the non myorelaxing hypnotic is a benzodiazepine hypnotic, preferably temazepam, brotizolam, flurazepam, nitrazepam, or triazolam.~~

30. The use of claim 21, wherein the non myorelaxing hypnotic is a non-benzodiazepine hypnotic, preferably a cyclopyrrolone hypnotic, preferably selected from the group consisting of zolpidem, zopiclone, and eszopiclone; gabapentin; trazodone; diphenhydramine; suvorexant; tasimelteon; ramelteon; agomelatine; doxepin; zaleplon; doxylamine; sodium oxybate; or tiagabine.

31. The use of claim 21, wherein the non myorelaxing hypnotic is in an immediate release formulation.

32. The use of claim 21, wherein the non myorelaxing hypnotic is in an extended release formulation.

33. The use of any one of claims 21-32, wherein the non myorelaxing hypnotic is zolpidem.

34. The use of any one of claims 21-32, wherein the non myorelaxing hypnotic is trazodone.

35. The use of claim 33, wherein the zolpidem is to be administered at a dose of 2-12.5 mg.

36. The use of claim 35, wherein the zolpidem is in an immediate release formulation with a dose of 2 – 10 mg.

37. The use of claim 35, wherein the zolpidem is in an extended release formulation with a dose of 5 – 12.5 mg.

38. The use of claim 21, wherein the 5-HT2A inverse agonist is AC-90179, ketanserin, nelotanserin, eplivanserin, pimavanserin, or volinanserin; or the 5-HT2A antagonist is trazodone, mirtazapine, ketanserin, clozapine, olanzapine, quetiapine, risperidone, iloperidone, perospirone, asenapine, nefazodone, MDL-100,907, cyproheptadine, pizotifen, LY-367,265, 2-alkyl-4-aryl-tetrahydro-pyrimido-azepines, haloperidol, chlorpromazine, hydroxyzine (Atarax), 5-MeO-NBpBrT, or Niaprazine.

~~39~~20. The use of claim ~~38~~12, wherein the ~~5-HT2A inverse agonist or antagonist is~~ pimavanserin~~, preferably~~is to be administered at a dose of 20-40 mg, preferably 34 mg.

~~40~~21. The use of any one of claims ~~21-39~~12-20, wherein the disease or disorder is Obstructive Sleep Apnea or Simple Snoring.

~~41~~22. The use of claim ~~40~~21, wherein the disease or disorder is Obstructive Sleep Apnea.

~~42~~23. The use of claim ~~21~~12, wherein the non-fully conscious state is sleep.

~~43~~24. The use of claim ~~21~~12, wherein the NRI and the pimavanserin ~~non myorelaxing hypnotic~~ are to be administered in a single composition.

~~44~~25. The use of claim ~~43~~24, wherein the single composition is an oral administration form.

~~45~~26. The use of claim ~~44~~25, wherein the oral administration form is a syrup, pill, tablet, troche, or capsule.